In this issue:
IV drug use: no barrier to HCV therapy
Telaprevir improves HCV treatment response
High SVR with short telaprevir-based regimen
Telaprevir improves SVR rate in non-responders
New PIs for HCV prove cost-effective
Rising mortality from HCV in the USA
Birth-cohort screening for HCV cost-effective
HIV transmission risks
HCV SVR improves cerebral functioning
Rapid HCV screening using an oral swab
Please login below to download this issue (PDF)